Effects of Polymorphisms in Myc-Related Genes on Bleeding Complications in Patients with Stable Warfarin Responses
Table 1
Patient characteristics of study patients.
Characteristics
Bleeding complication, number (%)
p
Presence (n = 21)
Absence (n = 121)
Sex
0.705
Male
8 (38.1)
44 (36.4)
Female
13 (61.9)
77 (63.6)
Age (years)
0.106
Mean ± SD
62.0 ± 11.2
58.7 ± 10.0
Body weight (kg)
0.989
Mean ± SD
58.6 ± 10.7
58.7 ± 10.4
Body mass index (kg/m2)
0.756
Mean ± SD
22.3 ± 2.3
22.5 ± 2.8
Comorbidity
Hypertension
6 (28.6)
33 (27.3)
0.902
Diabetes mellitus
3 (14.3)
10 (8.3)
0.377
Chronic heart failure
7 (33.3)
25 (20.7)
0.199
Atrial fibrillation
17 (81)
70 (57.9)
0.045
Myocardial infarction
2 (9.5)
2 (1.7)
0.104
Comedication
Angiotensin-converting-enzyme inhibitor
2 (10.5)
19 (18.8)
0.383
Angiotensin II receptor blocker
4 (21.1)
19 (18.8)
0.820
Antiplatelet drugs
0 (0)
4 (3.8)
0.398
Calcium channel blocker
4 (21.1)
19 (18.8)
0.820
Diuretics
9 (47.4)
35 (34.7)
0.291
Statins
0 (0)
4 (4.0)
0.378
Valve position
0.740
Aortic
6 (28.6)
28 (23.1)
Mitral
9 (42.9)
66 (54.5)
Double
5 (23.8)
20 (16.5)
Tricuspid
1 (4.8)
7 (5.8)
Valve type
0.418
St. Jude Medical
7 (38.9)
39 (34.2)
CarboMedics
6 (33.3)
32 (28.1)
ATS
2 (11.1)
15 (13.2)
MIRA
1 (5.6)
9 (7.9)
Duromedics
2 (11.1)
6 (5.3)
OnX
0 (0)
4 (3.5)
Others
0 (0)
9 (7.9)
International normalized ratio
0.143
Mean ± SD
2.41 ± 0.07
2.45 ± 0.10
Follow-up time (years)
0.886
Median (range)
14.3 (1.4 - 29.7)
14.7 (1.0 – 27.7)
Aortic plus mitral valve; tricuspid valve with or without other valves; including Sorin, Bjork Shiley, D-ring, and prostheses using two or more different valve types.
